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Abstract
Background:  To compare intracavitary brachytherapy (ICBT) planning methods for cervical
cancer, based on either orthogonal radiographs (conventional plan) or CT sections (CT plan); the
comparison focused on target volume coverage and dose volume analysis of organs at risk (OARs),
by representing point doses defined by the International Commission on Radiation Units and
Measurement (ICRU) and dose volume histograms (DVHs) from 3D planning.
Methods: We analyzed the dosimetric data for 62 conventional and CT-based ICBT plans. The
gross tumor volume (GTV), clinical target volume (CTV) and organs at risk (OAR)s were
contoured on the CT-plan. Point A and ICRU 38 rectal and bladder points were defined on
reconstructed CT images.
Results: Patients were categorized on the basis of whether the >95% isodose line of the point-A
prescription dose encompassed the CTV (group 1, n = 24) or not (group 2, n = 38). The mean GTV
and CTV (8.1 cc and 20.6 cc) were smaller in group 1 than in group 2 (24.7 cc and 48.4 cc) (P
<0.001). The mean percentage of GTV and CTV coverage with the 7 Gy isodose was 93.1% and
88.2% for all patients, and decreased with increasing tumor size and stage. The mean D2 and D5
rectum doses were 1.66 and 1.42 times higher than the corresponding ICRU point doses and the
mean D2 and D5 bladder doses were 1.51 and 1.28 times higher. The differences between the
ICRU dose and the D2 and D5 doses were significantly higher in group 2 than in group 1 for the
bladder, but not for the rectum.
Conclusion: The CT-plan is superior to the conventional plan in target volume coverage and
appropriate evaluation of OARs, as the conventional plan overestimates tumor doses and
underestimates OAR doses.
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Background
Intracavitary brachytherapy (ICBT) with external radio-
therapy (ERT) is an essential component of cervical cancer
management and has a high therapeutic index by deliver-
ing a high dose to the primary cervical lesion and lower
doses to adjacent organs, resulting in increased local con-
trol and survival without increased in toxicity [1-4]. How-
ever the doses delivered to tumor and normal tissues from
ICBT are difficult to quantify accurately in conventional
brachytherapy (BRT) planning. To ensure consistency in
the reporting of ICBT applications in cervical cancer, the
International Commission on Radiation Units and Meas-
urement (ICRU) recommended a number of parameters
for doses and volumes to be considered. These include
points A and B, representing the doses in the parametria
and the pelvic wall, and the rectal and bladder points rep-
resenting the organs at risk (OARs), respectively [5]. Phy-
sicians have used these reference point doses to report
treatment intensity and to estimate the maximal dose to
normal tissues, which can predict late complications.
However, the conventional plan in treating cervical cancer
may not correspond with the individual extent of the
tumor. This may result in either undercoverage of the
tumor or overdosage of the surrounding normal tissue.
A modern approach in treatment planning for cervical car-
cinoma is based on computed tomography (CT) sections
and on a 3D dose distribution. This allows better assess-
ment of dose distributions in different volumes, such as
the gross tumor volume (GTV), clinical target volume
(CTV), and OARs (rectum, bladder, and intestines). Ling
et al. published the first report describing the volumetric
dose distributions from ICBT [6]. In 2004, guidelines were
published for proposing image-based BRT for cervical
cancer [2]. However, the results of the first preliminary
studies indicated that a great deal can be learned from vol-
umetric analysis of ICBT dose distributions [7-9]. Further-
more, the actual doses delivered to the tumor, bladder,
and rectum during ICBT do not correlate well with those
estimated from ICRU reference-dose calculations, demon-
strating that the point A dose in conventional plans over-
estimates the target volume dose coverage and
underestimates the OAR doses determined by CT plans
[10-12].
Although conventional treatment planning has generally
yielded high tumor control rates, with a low frequency of
major complications, a more accurate understanding of
the radiation doses delivered during ICBT may lead to
improved treatment outcomes. In an attempt to solve
some of the problems that have limited the use of volu-
metric analysis of ICBT dose distributions and to achieve
a better understanding of the treatments, we compared
two treatment planning methods based on orthogonal
radiographs (conventional plan) and CT sections (CT
plan). The comparison was based on point doses defined
by the ICRU and dose volume histograms (DVHs) from
3D planning.
Methods
Patient Characteristics
Between January 2008 and August 2008, 29 patients with
uterine cervical cancer underwent radical concurrent
chemoradiotherapy consisting of weekly cisplatin plus
radiotherapy in the Department of Radiation Oncology at
Baskent University in Adana, Turkey. Sixty-two BRT plans
were evaluated. All patients were evaluated for staging
with a thorough gynecological examination under
anesthesia. Magnetic resonance imaging (MRI) was per-
formed to assess local tumor extension and tumor size,
and flouro-deoxyglucose (FDG) positron-emission tom-
ography (PET-CT) was performed to assess lymph node
and distant metastases. Baskent University's Institutional
Review Board approved this study design.
Treatment
The treatment consists of a combination of ERT with con-
current weekly 40 mg/m2 cisplatin and high dose rate
(HDR) BRT. All ERT was planned with a four-field box
technique using a treatment planning system (Eclipse®,
Varian Medical Systems, Palo Alto, CA, USA). A total of
50.4 Gy (1.8 Gy/fr, daily, Monday through Friday) was
delivered using 18-MV photons. Brachytherapy was per-
formed with a remote afterloading HDR unit with a radi-
oactive Iridium-192 source (Varisource®, Varian Medical
Systems). The ICBT procedure was initiated at the end of
ERT. The median amount of time between the completion
of ERT and the first BRT application was 2 days (range 1–
5 days). The planned dose per fraction was 7 Gy pre-
scribed to point A, given in 4 fractions, and the BRT was
delivered twice weekly.
A CT compatible Fletcher-Suit applicators were used dur-
ing ICBT application and consisted of uterine tandem
with various angles (15°, 30°, 45°) and a pair of ovoids
with various diameters (20, 25, 30 mm). Before each
application, a urinary catheter was inserted and the cathe-
ter balloon inflated with contrast media (7 mL) to localize
the bladder neck. Patients were not given specific instruc-
tions for rectal preparation, but they were encouraged to
empty their bowels before a simulation procedure and
before the next ICBT procedure. Appropriate anterior and
posterior vaginal packing was used to fix the applicator
position and to displace the bladder and rectum away
from the vaginal applicators. After the intracavitary appli-
cation, the applicator was fixed with a universal applicator
clamping device (Varian®), which was underneath the
patient. All patients underwent both conventional and 3D
planning. To minimize patient movement during both
the orthogonal films and CT scans, every attempt wasJournal of Experimental & Clinical Cancer Research 2009, 28:95 http://www.jeccr.com/content/28/1/95
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made to keep the applicator in position and to complete
the entire procedure within the shortest possible time.
First, patients underwent orthogonal radiographic pelvic
films for dose calculation. During conventional dose cal-
culation, CT scans of the pelvis were performed with CT
compatible applicators. Since the applicators are CT com-
patible, the shields were not used in order to overcome
artifacts during CT scans.
Conventional Planning
All patients had traditional radiography based treatment
plans. The radiation source position, point A (left and
right), point B (left and right), and ICRU reference blad-
der and rectal points were inserted in the planning system
using orthogonal radiographic films obtained with metal-
lic dummy markers inserted inside the applicator. The
ICRU bladder reference point was identified using a Foley
catheter, with the balloon filled with 7.0 mL of contrast
material. The rectal point was defined as 5 mm behind the
posterior vaginal wall (ICRU reference point), which
could be visualized by radiopaque gauze used for the vag-
inal packing. The 7 Gy dose was optimized to Point A
without making any modifications, such as weighting.
During conventional planning, the doses to point A (right
and left) point B (right and left), and the bladder and rec-
tum were calculated. At the same time, volumes of the
dose matrix receiving 50% (3.5 Gy), 100% (7 Gy), 150%
(10.5 Gy), and 200% (14 Gy) of point A doses were com-
puted.
3D CT-Planning
A CT scan with 2.5-mm slice thickness through the pelvis
was performed for each HDR BRT in each patient with the
CT compatible applicator in place. All CT slices were
transferred, via a hospital network, to the treatment plan-
ning system (Brachyvision® v 7.5, Varian Medical Systems)
before a physician contoured the target volume and OARs
on each slice of the CT scan. Dwell positions inside of the
uterine tandem and ovoids were identified automatically
from CT images using the planning system. The dose was
optimized to target (CTV) minimum in order to receive at
least prescribed 7 Gy. Delineation of the GTV was per-
formed based on CT information at the time of the BRT
and supported by clinical and radiographic findings, as
recommended by 'Image-guided Brachytherapy Working
Group'[2]. The Working Group proposes that the primary
GTV be that defined through imaging plus any clinically
visualized or palpable tumor extensions. This volume is
meant to include the entire determinable tumor (the pri-
mary tumor in the cervix and its extensions to the parame-
tria as determined by MRI plus the clinical examination).
A safety margin for the GTV, which defines the CTV at the
time of BRT, was calculated. In practice, the CTV covers
the cervix plus the presumed tumor extension, reflecting
macroscopic and microscopic residual disease at the time
of BRT, which was proposed by the working group [2]. If
the tumor extension at diagnosis was confined to the cer-
vix proper, the CTV simply included the whole cervix. If
there was parametrial infiltration, the depth of infiltration
was estimated, and the safety margin was modified
according to the parametrial infiltration depth. If the
images showed a normal configuration of the corpus
uteri, only the central part of the corpus was enclosed. If
there was involvement of the fornices or the proximal
vagina, these parts were included as well. Moreover, intra-
observer variability was also assessed on 10 sample plans
by a blind repetition of CTV contouring on randomly cho-
sen CT scans. The average intraobserver variability was 0.5
mm and 0.7 mm for the cranial and caudal margins,
respectively, with a maximum 0.9 mm intra-observer var-
iation at the caudal limit of the CTV, which is in close
proximity with literature findings [13,14].
Besides GTV, the external contour of the bladder, rectum,
sigmoid colon, and small bowel in the pelvis were deline-
ated on each CT slice by one physician. In this study, the
rectum was delineated from the anal verge to the rectosig-
moid junction, and the sigmoid colon was defined as the
large bowel above the rectum to the level of the lumbosac-
ral interspace. The bowel excluding the sigmoid colon and
rectum in the pelvis was defined as small bowel.
After the ICRU reference points were identified on orthog-
onal films, they were transposed to CT images by co-regis-
tering the orthogonal films and digitally reconstructed
radiographs (DRRs) obtained from CT scans. By this
method, the point A dose simply transferred from the
conventional plan to the conformal plan and then cover-
age compared. For co-registration, the software required
the user to identify an origin, which was the external os in
this study. As the external os was digitized on radiograph
and CT, all reference points marked on orthogonal films
were automatically transferred to CT films.
The DVHs of tumor volumes and OARs were created for
each application. The volumes were calculated for the
dose matrices receiving 50% (3.5 Gy), 100% (7 Gy),
150% (10.5 Gy), and 200% (14 Gy) of the point-A doses
obtained from the conventional plan and the 3D CT plan.
The extent of tumor coverage within the prescribed 7 Gy
isodose volume obtained from orthogonal films and CT
were compared. To compare the respective ICRU rectal
and bladder point doses with the 3D volume dose, the
minimum dose value in the 2.0-cc volume receiving the
highest dose (D2) was determined from DVHs for blad-
der, rectum. The dose of a 5-cc volume (D5), which is
defined as the minimum dose value in the 5.0-cc volume
receiving the highest dose, was also calculated, because
this volume was previously reported as the minimal vol-
ume required for fistula formation [7,8,15]. The Student'sJournal of Experimental & Clinical Cancer Research 2009, 28:95 http://www.jeccr.com/content/28/1/95
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t test was performed for comparison of GTV, CTV, rectum,
bladder, sigmoid colon, and small bowel volumes
between groups. A comparison of the conventional plan
and CT-plan was performed using the Wilcoxon signed-
ranks test for all doses and volumes. P values less than
0.05 were considered statistically significant.
Results
The mean age of the patients was 56 years (range, 26–77
years). Tumor stage was evaluated according to the Inter-
national Federation of Gynecology and Obstetrics (FIGO)
classification [16]. Two patients (7%) had Stage IB2, 3
(10%) had Stage IIA, 15 (52%) had Stage IIB, 1 (3%) had
Stage IIIA, and 8 (28%) had Stage IIIB disease. Plans were
categorized into group 1 (n = 24, 39%), where > 95% of
the isodose line prescribed to point A in the conventional
plan encompassed the CTV, and group 2 (n = 38, 61%),
where < 95% of the prescribed point-A dose on the CT
plan encompassed the CTV. The mean GTV and CTV in all
patients were 14.1 cc (2.1–38.2 cc) and 36.3 cc (9.7–80.0
cc), respectively. The mean GTV, CTV, rectum, bladder,
sigmoid, and bowel volumes according to groups are pre-
sented in Table 1. The mean GTV and CTV were smaller in
group 1 than in group 2 (P < 0.001). The rectum, bladder,
sigmoid colon, and small bowel volumes in all patients
were 81.6 cc (37.5–177.6 cc), 60.3 cc (30.1–114.5 cc),
40.2 cc (10.8–62.8 cc), and 499.6 (158.1–973.3 cc),
respectively. No significant differences were found
between groups 1 and 2 in mean OAR volumes (Table 1).
The volumes of the dose matrices for all patients receiving
50% (3.5 Gy), 100% (7 Gy), 150% (10.5 Gy), and 200%
(14 Gy) of the point-A doses are shown in Figure 1. The
mean isodose volumes at 3.5 and 7 Gy were significantly
larger by CT-planning than by conventional planning (P <
0.001 and P = 0.01, respectively). However, no difference
was found between conventional planning and CT-plan-
ning for the 10.5 and 14 Gy isodose volumes. Table 2
shows the volumes of the dose matrices receiving 50%
(3.5 Gy), 100% (7 Gy), 150% (10.5 Gy), and 200% (14
Gy) of the point-A doses obtained from the conventional
plan and 3D CT plan according to groups. With the con-
ventional plan, the dose matrices receiving 50%, 100%,
150%, and 200% did not differ between groups. In both
groups, the 7 Gy isodose volumes were significantly larger
with the CT plan than with the conventional plan: 191.1
vs. 132.4 cc (P = 0.02), respectively, in group 1, and 266.8
vs. 137.4 cc (P <0.001), respectively, in group 2.
Target volume coverage
When the dose was prescribed to point A, the mean per-
centage of GTV and CTV encompassed within the 7 Gy
isodose level was 93.1% (74.4–100%) and 88.2% (58.8–
100%) with CT plan respectively. The target volume cov-
erage was inversely related to the volume of the target and
the extension of tumor (Figures 2 and 3). In patients with
larger tumors or tumors extending to the vagina or para-
metrium, the 7 Gy isodose line was more likely to not
fully cover the GTV (Pearson correlation: -0.82, P < 0.001)
and CTV (Pearson correlation: -0.80, P < 0.001) obtained
from CT.
The mean GTV volumes according to stages were, 7.3 cc
(3.5–11.9 cc) for IB2, 11.8 cc (5.1–34.6 cc) for IIA, 13.8 cc
(6.1–36.5 cc) for IIB, 15.2 cc (7.8–34.2 cc) for IIIA, and
26.2 cc (7.6–48.2 cc) for IIIB diseases. Since GTVs were
larger with the more advanced clinical stages, the GTV
coverage with the 7 Gy isodose volumes decreased with
increased tumor size and more advanced stage (Table 3).
For stages IB2, IIA, IIB, IIIA, and IIIB, the mean CTV was
23.8 cc (12.6–33.9 cc), 31.0 cc (17.5–72.5 cc), 32.1 cc
(18.1–74.2 cc), 37.3 cc (15.8–74.5 cc), and 56.0 cc (22.6–
89.9 cc), respectively. Similarly the CTV coverage with the
7 Gy isodose volumes diminished with more advanced
stage (Table 3).
Table 1: Mean values of GTV, CTV, and rectum, bladder, 
sigmoid colon, and small bowel volumes according to groups.
Group 1
(cc ± SD)
Group 2
(cc ± SD)
P
GTV 8.1 ± 5.4 20.6 ± 12.3 < 0.001
CTV 24.7 ± 10.7 48.4 ± 20.8 < 0.001
Rectum 76.1 ± 37.7 82.3 ± 36.9 0.19
Bladder 57.8 ± 19.5 63.0 ± 19.9 0.24
Sigmoid colon 38.2 ± 15.2 40.5 ± 16.3 0.72
Small bowel 508.9 ± 193.6 488.9 ± 226.1 0.68
*Abbreviations: GTV = gross tumor volume, CTV = clinical target 
volume, Group 1 = CTV coverage > 95% isodose line prescribed to 
point A, Group 2 = CTV coverage < 95% isodose line prescribed to 
point A.
Table 2: The volumes of the dose matrix receiving 50% (3.5 Gy), 
100% (7 Gy), 150% (10.5 Gy), and 200% (14 Gy) of point-A doses 
obtained from the conventional plan and the 3D CT plan 
according to groups.
Group 1 (cc) Group 2 (cc) P
Conventional plan
3.5 Gy 346.0 ± 81.3 375.4 ± 90.7 0.14
7 Gy 132.4 ± 31.5 137.4 ± 27.0 0.46
10.5 Gy 70.8 ± 18.6 69.5 ± 13.5 0.72
14 Gy 42.4 ± 12.8 41.7 ± 8.7 0.76
3D CT plan
3.5 Gy 521.2 ± 127.3 685.7 ± 146.0 < 0.001
7 Gy 191.1 ± 46.5 266.8 ± 81.3 < 0.001
10.5 Gy 98.7 ± 26.5 135.1 ± 39.0 < 0.001
14 Gy 60.2 ± 18.4 78.9 ± 22.1 0.003
*Abbreviations: Group 1 = CTV coverage > 95% isodose line 
prescribed to point A, Group 2 = CTV coverage < 95% isodose line 
prescribed to point A.Journal of Experimental & Clinical Cancer Research 2009, 28:95 http://www.jeccr.com/content/28/1/95
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Rectum doses
We compared the ICRU rectum and bladder point doses,
based on the conventional plan, with the D2 and D5 of
the rectum and bladder, based on the CT-plan. The mean
ICRU rectal dose obtained from the conventional plan for
all patients was 5.0 Gy (2.2–10.7 Gy), and the mean D2
and D5 of the rectum obtained from the 3D plan were 8.3
Gy (5.1–12.3 Gy) and 7.1 Gy (4.5–11.1 Gy), respectively.
The mean D2 and D5 of the rectum were 1.66 and 1.42
times higher than the mean ICRU rectum dose. The paired
difference between ICRU rectum point dose and D2 (P <
0.001), and D5 (P < 0.001) demonstrated a significant dif-
ference for all patients (Table 4).
The mean rectum ICRU point doses and D2 and D5 val-
ues did not differ significantly between groups 1 and 2
(Table 4). However, within each group, the differences
between the ICRU rectum dose and D2, and between the
ICRU rectum dose and D5 were significant. The differ-
ences in rectum doses between ICRU and D2, and ICRU
and D5 were greater in group 2 than in group 1, but this
did not reach statistical significance (Table 5).
Bladder doses
The mean ICRU bladder dose and D2 and D5 of the blad-
der for all patients were 6.1 Gy (2.9–8.7 Gy), 9.2 Gy (7.6–
12.9 Gy), and 7.2 Gy (3.4–10.9 Gy), respectively. The
mean D2 and D5 of the bladder were 1.51 and 1.28 times
higher than the mean ICRU bladder dose (6.1 Gy and 5.6
Gy). The differences of means between the ICRU bladder
dose points from the conventional plan and the D2 (p <
0.001) and D5 (p < 0.001) of the bladder from the CT
plan were statistically significant.
The mean ICRU bladder doses did not differ between
groups 1 and 2. However, D2 and D5 values were signifi-
cantly higher in group 2 than in group 1 (Table 5). Like-
wise, there were significant differences between ICRU
bladder and D2 values (p < 0.001) and D5 values (p <
0.001) for groups 1 and 2. The difference in the ICRU
bladder point dose and D2, and the ICRU bladder point
dose and D5 was significantly higher in group 2 than in
group 1 (Table 5).
Comparison of sigmoid colon and small bowel doses
The mean sigmoid colon and small bowel doses for all
patients were 6.5 Gy (2.6–11.2 Gy) and 5.1 Gy (2.1–9.8
Gy), respectively, for D2; and 6.8 Gy (2.0–11.5 Gy) and
5.6 Gy (1.8–9.7 Gy), respectively, for D5. The D2 and D5
values for sigmoid colon were significantly higher in
group 2 than in group 1 (up to 15%) (Table 4). Although
the D2 and D5 values for the small bowel were also higher
in group 2 than in group 1, the difference did not reach
statistical significance.
Mean values of isodose volumes covering 50%, 100%, 150% and 200% of prescribed Point A 7 Gy dose Figure 1
Mean values of isodose volumes covering 50%, 100%, 150% and 200% of prescribed Point A 7 Gy dose.Journal of Experimental & Clinical Cancer Research 2009, 28:95 http://www.jeccr.com/content/28/1/95
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Discussion
In the current study, we assessed the conventional BRT
plan based on ICRU reference points and the CT-based
BRT plan in patients with cervical cancer. We clearly dem-
onstrated that tumor volume coverage was inadequate in
the conventional plan compared to the CT-plan, and was
inversely related with the volume of the target and the
extension of tumor. With the conventional plan, the ICRU
rectum and bladder point doses underestimated the
actual rectum and bladder doses obtained from the CT-
plan. Additionally, we demonstrated that more precise
analysis of the dose received by certain volume of OARs
can be accomplished by utilizing the DVHs on CT-plans,
which may be of critical importance in regard to normal
tissue tolerance limits.
After publication of ICRU 38 report, ICRU reference
points for tumors, and reference dose points for bladder
and rectum were used for defining the doses in conven-
tional plans. But calculation of doses with these fixed ref-
erence points relative to applicators has certain
limitations. The conventional plan with the point-A dose
calculation relies on reference points on orthogonal films,
not tumor volumes defined on CT, which may cause
underestimation of tumor doses. Likewise, the calculation
of rectum and bladder doses made with ICRU reference
points, not with rectum and bladder volumes, may not
reflect the actual organ doses. In addition, sigmoid colon
and small bowel in the pelvis may be in close proximity to
the BRT sources during application, and the doses to these
organs should also be assessed. Since the ICRU did not
Scatter-plot for gross tumor volume (GTV) vs. percentage of coverage of these volumes by the 7 Gy isodose Figure 2
Scatter-plot for gross tumor volume (GTV) vs. percentage of coverage of these volumes by the 7 Gy isodose.Journal of Experimental & Clinical Cancer Research 2009, 28:95 http://www.jeccr.com/content/28/1/95
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define standard points for the sigmoid colon and small
bowel, it is not possible to evaluate doses to these organs
with conventional plans. To overcome such problems,
CT-guided 3D BRT treatment planning has been used suc-
cessfully for customizing the dose distribution according
to tumor extent and providing detailed dose-volume
information on the target volumes and surrounding tis-
sues [12,17-21].
Some investigators have reported that the point A-dose in
the conventional plan overestimates the target volume
dose coverage [10-12]. In addition, more advanced tumor
Scatter-plot for clinical target volume (CTV) vs. percentage of coverage of these volumes by the 7 Gy isodose Figure 3
Scatter-plot for clinical target volume (CTV) vs. percentage of coverage of these volumes by the 7 Gy isodose.
Table 3: Mean GTV and CTV and coverage of these volumes by the 7 Gy isodose according to clinical stage.
Stage GTV volume (cc) GTV coverage (%) CTV volume (cc) CTV coverage (%)
IB2 7.3 99.9 23.8 98.9
IIA 11.8 97.1 31.0 94.4
IIB 13.8 94.4 32.1 89.9
IIIA 15.2 93.5 37.3 90.6
IIIB 26.2 86.5 56.0 77.9
*Abbreviations: GTV = gross tumor volume, CTV = clinical target volume.Journal of Experimental & Clinical Cancer Research 2009, 28:95 http://www.jeccr.com/content/28/1/95
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stages and larger target volumes receive less coverage with
the prescribed dose, which may result in poor local con-
trol [12,22]. Datta et al. demonstrated that the percentage
of tumor encompassed within the point-A dose envelope
ranged from 60.8% to 100%, and this percentage
depended on the tumor volume at the time of ICBT [18].
In the current study, we demonstrated that the mean per-
centage of GTV and CTV encompassed within the point-A
7 Gy isodose level was 93.1% (74.4%–100%) and 88.2%
(58.8%–100%), respectively. Inadequate tumor coverage
could significantly influence the treatment outcome in
patients, especially in those who have partial regression of
tumors with gross residual tumor after ERT. Thus, tumors
with larger volumes at ICBT were more likely to have por-
tions outside the 7 Gy prescribed isodose line (Figures 2
and 3). Initially, Kim et al. demonstrated that the CT-plan
would be beneficial in patients with large CTVs, which
could not be fully encompassed by the 100% isodose line
[12]. In the current study, the GTV and CTV were larger in
group 2 than in group 1; therefore, the CT-plan would be
most beneficial in group 2. Although the isodose matrix
volumes did not differ between the two groups with the
conventional plan, these volumes were higher in group 2
with the CT-plan (Table 2), which may cause a significant
incremental dose to the neighboring tissues, mainly the
bladder and sigmoid colon (Table 3).
Although tumor shrinkage before BRT applications may
take place after ERT, the initial tumor stage, which reflects
the tumor extension, may negatively impact tumor cover-
age [1,22,23]. Kim et al. demonstrated that GTV but not
CTV increased with advanced stages [23]. They also found
that the percentages of the GTV encompassed by the 6 Gy
isodose line were 98.5%, 89.5%, 79.5%, and 59.5% for
stages IB1, IB2, IIB, and IIIB, respectively. In our study, the
GTV and CTV appeared to increase with more advanced
clinical stages. Meanwhile, tumor coverage within the 7
Gy isodose line diminished with more advanced clinical
stages (Table 3). Therefore, a higher stage of tumor
received less coverage by the prescribed point-A dose
because of extension to the parametria and/or vagina.
For evaluating the maximum doses to OARs, the dose to a
clinically significant volume is used; that clinically signif-
icant volume can be defined as the volume exposed to a
minimum dose in the part of the OAR that receives the
highest dose. The size of this volume can be absolute (e.g.,
1, 2, 5, or 10 cc) or relative (e.g., 1%, 2%, 5%, or 10% of
the contoured OAR). Several investigators have compared
the dose volume based on either the exterior organ con-
tour or only the organ wall, for the bladder and rectum
[8,24,25]. To evaluate organ wall dose correctly, the vol-
ume of 2.0 cc is considered, because the D2 computed for
the external contour are almost the same as the D2 to the
organ wall. Also, this 2.0 cc volume of tissue in the highest
dose region is probably more clinically relevant. Although
the difference between the DVHs increases greatly for vol-
umes larger than 2.0 cc, we also chose the dose of a 5-cc
volume (D5), because this volume was previously
reported as the minimal volume required for fistula for-
mation [7,8].
The rectum and bladder doses were found to be greater
than the corresponding ICRU reference doses
[7,8,12,18,26]. In these other studies, the true bladder and
rectum doses were 1.5–2.5 times greater than the corre-
sponding ICRU reference point doses. Pellioski et al. com-
pared the minimal doses delivered to 2 cc of the bladder
and rectum (DBV2 and DRV2) and found that ICRU bladder
reference point dose was significantly lower than the DBV2,
but the ICRU rectum reference point dose was not signifi-
Table 4: Mean values of organs at risk using the ICRU reference 
point doses with the conventional planning method and the D2 
and D5 values using the 3D CT planning method.
Group 1
Gy (%)
Group 2
Gy (%)
P
ICRU
Rectum 6.2 (89.0) 5.9 (84.7) 0.34
Bladder 5.2 (74.2) 4.9 (69.9) 0.51
D2
Rectum 8.1 (116.0) 8.5 (120.8) 0.46
Bladder 8.6 (122.3) 9.7 (138.8) 0.03
Sigmoid 5.9 (84.4) 7.1 (100.5) 0.009
Bowel 6.3 (90.1) 7.2 (103.5) 0.07
D5
Rectum 7.0 (100.0) 7.2 (103.5) 0.43
Bladder 7.3 (104.0) 8.2 (117.4) 0.03
Sigmoid 4.6 (65.4) 5.5 (78.2) 0.02
Bowel 5.3 (75.6) 5.8 (83.9) 0.2
*Abbreviations: Group 1 = CTV coverage > 95% isodose line 
prescribed to Point A, Group 2 = CTV coverage < 95% isodose line 
prescribed to Point A.
Table 5: Differences between ICRU rectum and bladder doses 
from orthogonal films and D2, and D5, of the rectum and 
bladder obtained from CT scans.
Variable Mean difference (Gy)
All patients Group 1 Group 2 P (1 vs.2)
Rectum
ICRU-D2 -3.3 -2.9 -3.6 0.24
ICRU-D5 -2.1 -1.8 -2.4 0.26
Bladder
ICRU-D2 -3.1 -2.3 -3.8 0.01
ICRU-D5 -1.7 -1.1 -2.3 0.01
*Abbreviations: Group 1 = CTV coverage > 95% isodose line 
prescribed to Point A, Group 2 = CTV coverage < 95% isodose line 
prescribed to Point A. D2 = the minimum dose value in the 2.0-cc 
volume receiving the highest dose, D5 = the minimum dose value in 
the 5.0-cc volume receiving the highest dose.Journal of Experimental & Clinical Cancer Research 2009, 28:95 http://www.jeccr.com/content/28/1/95
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cantly different from the DRV2 [26]. Our study indicated
that the maximum rectum and bladder D2 values were
1.66 and 1.51 times greater than the ICRU reference rec-
tum and bladder doses, respectively. We also found that
the maximum rectum and bladder D5 values were 1.42
and 1.28 times greater than the ICRU reference rectum
and bladder doses in CT plan. When we evaluated the dif-
ference between the ICRU rectum and bladder doses and
corresponding D2 and D5 values, the differences between
the ICRU bladder point dose and D2 and D5 bladder
doses were significantly higher in group 2 than in group 1;
however the difference in rectal doses did not differ signif-
icantly (Table 5).
Since the sigmoid colon and small bowel in the pelvis are
close to the radiation source during ICBT, doses received
by these organs should also be assessed. The ICRU defined
the reference points for bladder and rectum, the initial
dose calculations for these organs were performed during
the conventional plan. In addition, the doses to the sig-
moid colon and small bowel can be evaluated with the
CT-plan using DVHs. Al-Booz et al. pointed out that the
sigmoid colon received doses in excess of 70% of the
intended point-A dose during BRT [27]. Kim et al. demon-
strated that that the sigmoid colon received the highest
mean D2 when compared to the rectum and small bowel
[28]. Their study revealed that with the prescribed dose of
600 cGy, the sigmoid colon received the highest mean D2
(408 cGy) followed by the small bowel (379 cGy), and
rectum (373 cGy). In our study, we clearly demonstrated
that the small bowel D2 was higher than the sigmoid
colon D2 (6.8 Gy and 6.5 Gy, respectively). We also found
that the sigmoid colon D2 and D5 values were signifi-
cantly higher with larger CTVs (Table 4). The small bowel
D2 values were higher in group 2 than in group 1, and this
difference was almost statistically significant (P = 0.07).
The results of our study demonstrate that CT-guided BRT
planning is superior to conventional point A planning in
terms of both conformity of target coverage and evalua-
tion of OARs, including the sigmoid colon, bowel, blad-
der, and rectum. Although this superiority was clear for
small CTVs, for large CTVs both the conventional and CTV
plans had the drawbacks of inadequate target coverage
and/or excessive radiation doses to normal organs. To
ascertain the potential benefit of treatment outcomes,
such as tumor control probability and morbidity, ICR
with image-guided 3D planning will be pursued and cor-
related with the dose-volume parameters.
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